MA31433B1 - Inhibiteurs de la p70 s6 kinase - Google Patents

Inhibiteurs de la p70 s6 kinase

Info

Publication number
MA31433B1
MA31433B1 MA32404A MA32404A MA31433B1 MA 31433 B1 MA31433 B1 MA 31433B1 MA 32404 A MA32404 A MA 32404A MA 32404 A MA32404 A MA 32404A MA 31433 B1 MA31433 B1 MA 31433B1
Authority
MA
Morocco
Prior art keywords
inhibitors
inhibitors kinase
kinase
formula
methods
Prior art date
Application number
MA32404A
Other languages
Arabic (ar)
English (en)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L Holst
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31433B1 publication Critical patent/MA31433B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des inhibiteurs de la p70 s6 kinase de formule : des formulations pharmaceutiques comprenant ces inhibiteurs et leurs procédés d'utilisation.
MA32404A 2007-05-11 2009-12-07 Inhibiteurs de la p70 s6 kinase MA31433B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (fr) 2007-05-11 2008-05-01 Inhibiteurs de la p70 s6 kinase

Publications (1)

Publication Number Publication Date
MA31433B1 true MA31433B1 (fr) 2010-06-01

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32404A MA31433B1 (fr) 2007-05-11 2009-12-07 Inhibiteurs de la p70 s6 kinase

Country Status (33)

Country Link
US (2) US8093383B2 (fr)
EP (1) EP2148880B1 (fr)
JP (1) JP5503532B2 (fr)
KR (1) KR101088219B1 (fr)
CN (1) CN101679439B (fr)
AR (1) AR066344A1 (fr)
AU (1) AU2008251692B2 (fr)
BR (1) BRPI0811212A2 (fr)
CA (1) CA2687265C (fr)
CL (1) CL2008001230A1 (fr)
CO (1) CO6241109A2 (fr)
CR (1) CR11106A (fr)
DK (1) DK2148880T3 (fr)
DO (1) DOP2009000257A (fr)
EA (1) EA016445B1 (fr)
EC (1) ECSP099721A (fr)
ES (1) ES2483726T3 (fr)
GT (1) GT200900292A (fr)
HR (1) HRP20140611T1 (fr)
IL (1) IL201564A (fr)
MA (1) MA31433B1 (fr)
MX (1) MX2009012075A (fr)
MY (1) MY154898A (fr)
NZ (1) NZ580423A (fr)
PE (1) PE20090887A1 (fr)
PL (1) PL2148880T3 (fr)
PT (1) PT2148880E (fr)
RS (1) RS53451B (fr)
SI (1) SI2148880T1 (fr)
TN (1) TN2009000446A1 (fr)
TW (1) TWI423805B (fr)
UA (1) UA99284C2 (fr)
WO (1) WO2008140947A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
EP2355821A1 (fr) * 2008-11-11 2011-08-17 Eli Lilly and Company Thérapie combinant l'inhibiteur de p70 s6 kinase et l'inhibiteur d'egfr
EA018824B1 (ru) * 2008-11-11 2013-10-30 Эли Лилли Энд Компани КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРОМ КИНАЗЫ p70 S6 И ИНГИБИТОРОМ mTOR
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
WO2010093419A1 (fr) 2009-02-11 2010-08-19 Merck Patent Gmbh Nouveaux carboxamides amino-azahétérocycliques
AU2010281503B2 (en) 2009-08-07 2016-01-28 Merck Patent Gmbh Novel azaheterocyclic compounds
KR101398268B1 (ko) 2009-10-23 2014-05-23 일라이 릴리 앤드 캄파니 Ａｋｔ 억제제
EP2992878A1 (fr) 2010-02-03 2016-03-09 Signal Pharmaceuticals, LLC Identification d'une mutation lkb1 comme biomarqueur prédictif de la sensibilité aux inhibiteurs de la kinase tor
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
ES2729754T3 (es) 2010-07-29 2019-11-06 Merck Patent Gmbh Carboxamidas azaheterocíclicas de aminas cíclicas
PL2643313T3 (pl) 2010-11-24 2017-03-31 Merck Patent Gmbh Azetydyny chinazolino-karboksyamidowe
SI2755958T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Aminopirimidinski derivati za uporabo kot modulatorji kinazne aktivnosti
SG10201606301YA (en) * 2011-09-12 2016-09-29 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
ES2807539T3 (es) * 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
ES2821102T3 (es) 2012-11-29 2021-04-23 Merck Patent Gmbh Derivados de azaquinazolincarboxamida
US9458134B2 (en) * 2013-03-11 2016-10-04 Merck Patent Gmbh Heterocycles as modulators of kinase activity
CA2909579A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Therapie combinee comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide pour le traitement d'un cancer
WO2014172432A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Polythérapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
WO2014172431A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Polythérapie comportant un composé dihydropyrazino-pyrazine et un antagoniste d'un récepteur des androgènes pour le traitement du cancer de la prostate
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
TWI654979B (zh) 2013-04-17 2019-04-01 美商標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
KR102459285B1 (ko) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015134536A1 (fr) * 2014-03-04 2015-09-11 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications
SG11201608189WA (en) 2014-04-03 2016-10-28 Merck Patent Gmbh Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (fr) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
WO2016040078A1 (fr) * 2014-09-10 2016-03-17 Eli Lilly And Company Composés de phénylimidazolylpipéridyle substitués utilisés en tant qu'inhibiteurs de p70s6k1
WO2016164641A1 (fr) 2015-04-08 2016-10-13 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2021376892A1 (en) 2020-11-16 2023-06-29 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
WO2007003960A1 (fr) 2005-06-30 2007-01-11 Prosidion Limited Agonistes du gpcr
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
WO2008012635A2 (fr) 2006-07-26 2008-01-31 Pfizer Products Inc. Dérivés d'amines utiles en tant qu'agents anticancéreux
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EP2148880B1 (fr) 2014-05-28
AR066344A1 (es) 2009-08-12
US20090163714A1 (en) 2009-06-25
RS53451B (sr) 2014-12-31
US8093383B2 (en) 2012-01-10
CA2687265A1 (fr) 2008-11-20
TW200848053A (en) 2008-12-16
EP2148880A1 (fr) 2010-02-03
CN101679439B (zh) 2013-09-11
EA200971051A1 (ru) 2010-06-30
MX2009012075A (es) 2009-11-19
HK1140767A1 (en) 2010-10-22
CO6241109A2 (es) 2011-01-20
ES2483726T3 (es) 2014-08-07
KR20100005710A (ko) 2010-01-15
KR101088219B1 (ko) 2011-11-30
CR11106A (es) 2010-04-12
IL201564A (en) 2014-08-31
EA016445B1 (ru) 2012-05-30
ECSP099721A (es) 2009-12-28
IL201564A0 (en) 2010-05-31
WO2008140947A1 (fr) 2008-11-20
UA99284C2 (ru) 2012-08-10
PE20090887A1 (es) 2009-07-13
AU2008251692A1 (en) 2008-11-20
CA2687265C (fr) 2012-12-04
MY154898A (en) 2015-08-28
DOP2009000257A (es) 2010-03-31
BRPI0811212A2 (pt) 2014-10-29
CL2008001230A1 (es) 2009-05-22
CN101679439A (zh) 2010-03-24
DK2148880T3 (da) 2014-06-16
AU2008251692B2 (en) 2012-10-11
HRP20140611T1 (hr) 2014-08-15
TN2009000446A1 (en) 2011-03-31
JP5503532B2 (ja) 2014-05-28
TWI423805B (zh) 2014-01-21
US20120071490A1 (en) 2012-03-22
PT2148880E (pt) 2014-08-28
PL2148880T3 (pl) 2014-10-31
JP2010526814A (ja) 2010-08-05
NZ580423A (en) 2012-02-24
SI2148880T1 (sl) 2014-07-31
GT200900292A (es) 2011-06-24

Similar Documents

Publication Publication Date Title
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MA33492B1 (fr) Inhibiteurs de bace
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
NO20073601L (no) Immunresponsmodifikator-skumformuleringer
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MY148634A (en) Pyridazinone derivatives
EP2184984A4 (fr) Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
EA201170832A1 (ru) Пуриновые соединения
MA30042B1 (fr) Composes calcilytiques
MX2009010485A (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer